Literature DB >> 27997528

Losartan attenuates the coronary perivasculitis through its local and systemic anti-inflammatory properties in a murine model of Kawasaki disease.

Eisuke Suganuma1,2, Fumio Niimura1, Shinichi Matsuda1, Toshiko Ukawa1, Hideaki Nakamura1, Kaori Sekine1, Masahiko Kato1, Yuji Aiba3, Yasuhiro Koga3, Kuniyoshi Hayashi4, Osamu Takahashi4, Hiroyuki Mochizuki1.   

Abstract

BACKGROUND: Kawasaki disease is a common systemic vasculitis that leads to coronary artery lesions. Besides its antihypertensive effects, losartan can modulate inflammation in cardiovascular disease. We examined whether losartan can attenuate coronary inflammation in a murine model of Kawasaki disease. METHODS AND
RESULTS: Five-wk-old C57/BL6J male mice were intraperitoneally injected with Lactobacillus casei cell wall extract to induce coronary inflammation and divided into four groups: placebo, intravenous immunoglobulin (IVIG), losartan, and IVIG+losartan. After 2 wk, mice were harvested. The coronary perivasculitis was significantly attenuated by losartan but not by IVIG alone, and further dramatic attenuation by IVIG+losartan was observed. The frequency of Lactobacillus casei cell wall extract-induced myocarditis (80%) was markedly lowered by losartan (22%) and IVIG+losartan (0%). Furthermore, interleukin (IL)-6 mRNA was markedly attenuated by IVIG+losartan. Serum levels of IL-6, TNF-α, MCP-1, and IL-10 after Lactobacillus casei cell wall extract injection were slightly decreased by IVIG or losartan. Moreover, IL-1β, IL-10, and MCP-1 levels were significantly decreased by IVIG+losartan.
CONCLUSION: The addition of losartan to IVIG strongly attenuated the severity of coronary perivasculitis and the incidence of myocarditis, along with suppressing systemic/local cytokines as well as the activated macrophage infiltration. Therefore, losartan may be a potentially useful additive drug for the acute phase of Kawasaki disease to minimize coronary artery lesions.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27997528     DOI: 10.1038/pr.2016.266

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  38 in total

1.  Tissue Doppler Imaging as a Predictor of Immunoglobulin Resistance in Kawasaki Disease.

Authors:  Daniel Phadke; Sonali S Patel; Samuel R Dominguez; Heather Heizer; Marsha S Anderson; Mary P Glode; Pei-Ni Jone
Journal:  Pediatr Cardiol       Date:  2015-05-21       Impact factor: 1.655

2.  The treatment of Kawasaki syndrome with intravenous gamma globulin.

Authors:  J W Newburger; M Takahashi; J C Burns; A S Beiser; K J Chung; C E Duffy; M P Glode; W H Mason; V Reddy; S P Sanders
Journal:  N Engl J Med       Date:  1986-08-07       Impact factor: 91.245

3.  Progression and regression of atherosclerosis in APOE3-Leiden transgenic mice: an immunohistochemical study.

Authors:  M J Gijbels; M van der Cammen; L J van der Laan; J J Emeis; L M Havekes; M H Hofker; G Kraal
Journal:  Atherosclerosis       Date:  1999-03       Impact factor: 5.162

4.  Dramatic decrease of circulating levels of monocyte chemoattractant protein-1 in Kawasaki disease after gamma globulin treatment.

Authors:  M Terai; T Jibiki; A Harada; Y Terashima; K Yasukawa; S Tateno; H Hamada; S Oana; H Niimi; K Matsushima
Journal:  J Leukoc Biol       Date:  1999-05       Impact factor: 4.962

5.  Increased serum interleukin-10 level in Kawasaki disease.

Authors:  D S Kim; H K Lee; G W Noh; S I Lee; K Y Lee
Journal:  Yonsei Med J       Date:  1996-04       Impact factor: 2.759

6.  Angiotensin II amplifies macrophage-driven atherosclerosis.

Authors:  Ayabe Nobuhiko; Eisuke Suganuma; Vladimir R Babaev; Agnes Fogo; Larry L Swift; MacRae F Linton; Sergio Fazio; Iekuni Ichikawa; Valentina Kon
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-09-16       Impact factor: 8.311

7.  Coronary arteritis in mice following the systemic injection of group B Lactobacillus casei cell walls in aqueous suspension.

Authors:  T J Lehman; S M Walker; V Mahnovski; D McCurdy
Journal:  Arthritis Rheum       Date:  1985-06

8.  Angiotensin inhibition decreases progression of advanced atherosclerosis and stabilizes established atherosclerotic plaques.

Authors:  Eisuke Suganuma; Vladimir R Babaev; Masaru Motojima; Yiqin Zuo; Nobuhiko Ayabe; Agnes B Fogo; Iekuni Ichikawa; MacRae F Linton; Sergio Fazio; Valentina Kon
Journal:  J Am Soc Nephrol       Date:  2007-07-18       Impact factor: 10.121

9.  Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism.

Authors:  Jennifer P Habashi; Jefferson J Doyle; Tammy M Holm; Hamza Aziz; Florian Schoenhoff; Djahida Bedja; YiChun Chen; Alexandra N Modiri; Daniel P Judge; Harry C Dietz
Journal:  Science       Date:  2011-04-15       Impact factor: 47.728

10.  Important role of CCR2 in a murine model of coronary vasculitis.

Authors:  Hernan G Martinez; Marlon P Quinones; Fabio Jimenez; Carlos Estrada; Kassandra M Clark; Kazuo Suzuki; Noriko Miura; Naohito Ohno; Sunil K Ahuja; Seema S Ahuja
Journal:  BMC Immunol       Date:  2012-10-17       Impact factor: 3.615

View more
  3 in total

1.  A novel mouse model of coronary stenosis mimicking Kawasaki disease induced by Lactobacillus casei cell wall extract.

Authors:  Eisuke Suganuma; Satoshi Sato; Satoko Honda; Atsuko Nakazawa
Journal:  Exp Anim       Date:  2020-01-13

Review 2.  Immunomodulatory Activity of the Most Commonly Used Antihypertensive Drugs-Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers.

Authors:  Paweł Bryniarski; Katarzyna Nazimek; Janusz Marcinkiewicz
Journal:  Int J Mol Sci       Date:  2022-02-04       Impact factor: 5.923

3.  Losartan improves intestinal mucositis induced by 5-fluorouracil in mice.

Authors:  Maisie Mitchele Barbosa Oliveira; Aurigena Antunes de Araújo; Susana Barbosa Ribeiro; Polyana Crislayne Moreira de Sales Mota; Vitória Barros Marques; Conceição da Silva Martins Rebouças; Jozi Godoy Figueiredo; Patrícia Batista Barra; Gerly Anne de Castro Brito; Renata Ferreira de Carvalho Leitão; Gerlane Coelho Bernardo Guerra; Caroline Addison Carvalho Xavier de Medeiros
Journal:  Sci Rep       Date:  2021-12-01       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.